Helmut Dolznig, Associate Professor at the Institute of Medical Genetics, as a member of an eight-member consortium between MedUni Vienna and VetMedUni Vienna, has received a highly endowed research grant from the Ludwig Boltzmann Gesellschaft and the BMFWF as part of a "Ludwig Boltzmann Clinical Research Group."
Using a precision medicine approach, Prof. Dolznig is playing a key role in testing new potential drugs in complex human organoid models of colon cancer, which also contain connective tissue cells and immune cells. These drugs will then be used for the first time in clinical trials at MedUni Vienna as part of the project: "Rational and Personalized Targeting of Chemotherapy Resistance in Gastrointestinal Cancer." These complex models were developed at the Institute of Medical Genetics by Helmut Dolznig and his research group in recent years and are physiologically highly relevant preclinical models that are predestined for testing established drugs as well as for screening and identifying new drugs.